Halozyme Prices Upsized $1.3 Billion Convertible Notes Offering

Key Facts

1Halozyme Therapeutics announced the pricing of a private offering of $1.3 billion in convertible senior notes due 2033.

2The offering size was upsized to $1.3 billion from the previously announced $1.05 billion, with a 1.50% interest rate.

In a move reflecting corporate strategies to bolster liquidity amid credit market shifts, Halozyme Therapeutics announced the pricing of a private offering of $1.3 billion in convertible senior notes due 2033. According to reports, the company upsized the offering from its initial $1.05 billion target, setting the annual interest rate at 1.50%. The firm intends to utilize a portion of the proceeds to repurchase outstanding convertible notes maturing in 2027 and 2028.

Per market data, the initial conversion price for the new notes is set at approximately $139.84 per share, representing a 27.5% premium over the recent closing price. This financing maneuver comes as companies leverage hybrid debt instruments to minimize direct interest costs, with the offering including capped call transactions at an initial cap price of $208.39 per share, a 90% premium over current trading levels.

At the close of September 17, 2026, HALO shares stood at $109.68, having fluctuated between a day high of $110.88 and a low of $106.82. Traders are now monitoring the impact of this issuance on the company's capital structure; with no immediate sector-specific catalysts in the upcoming calendar, focus remains on the execution of the planned debt repurchases.